<DOC>
	<DOCNO>NCT00711412</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give capecitabine oxaliplatin together radiation therapy work treat patient esophageal gastroesophageal junction cancer .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin , Radiation Therapy Treating Patients With Esophageal Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathologic complete response patient adenocarcinoma esophagus gastroesophageal junction treat neoadjuvant therapy comprise capecitabine , oxaliplatin , radiotherapy . Secondary - Determine clinical response rate patient treat regimen . - Determine recurrence rate , time progression , patterns failure patient treat regimen . - Characterize toxicity profile regimen patient . OUTLINE : - Induction therapy : Patients receive oral capecitabine twice daily day 1-14 oxaliplatin IV 2 hour day 1 8 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . - Combination chemoradiotherapy : Patients receive oxaliplatin IV 2 hour weekly 6 week . Patients also receive concurrent oral capecitabine twice daily undergo radiotherapy daily 5 day week 5½ week absence disease progression unacceptable toxicity . - Surgery : Patients undergo surgical resection 4-8 week completion chemoradiotherapy . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma esophagus gastroesophageal junction Stage IIVA disease No distant metastatic disease ( regional lymph node ) No evidence CNS metastases CNS metastasis stable &gt; 3 month allow PATIENT CHARACTERISTICS : ECOG performance status 02 Consuming ≥ 1,500 calorie daily ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexisting neuropathy No prior unanticipated severe reaction fluoropyrimidine therapy No known hypersensitivity fluorouracil No know DPD deficiency No known hypersensitivity component oxaliplatin No significant active infection severe complicate medical illness No clinically significant cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia well controlled medication ) No myocardial infarction within past 12 month No history uncontrolled seizure , CNS disorder , psychiatric disability judge investigator clinically significant , preclude informed consent , interfere compliance oral drug intake No malabsorption syndrome No active malignancy within past 3 year except cervical carcinoma situ nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : More 4 week since prior participation investigational drug study No prior pelvic thoracic radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>